Rakesh Kumar, MD
Nephrology · Edgewood, KYNPI 1649427428
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,153 of the $4,435 with a category attached, or 71.1%. 31 manufacturers reported payments, led by Baxter Healthcare at 32.1% of the total. Reporting peaked in 2019 at $1,974 and has fallen 63.0% since, to $730 in 2025.
Across 176 payments — averaging $25.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Baxter Healthcare$1K
- Amgen$361
- Bayer$309
- Travere Therapeutics, Inc.$300
- Vifor Pharma, Inc.$239
- OPKO Pharmaceuticals, LLC$227
- plus $2K from 25 others
What the payments were for
- Travel & lodging$1,11925%
- Food & beverage$3,15371%
- Education$1634%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Baxter Healthcare | 9 | $1,423 |
| Amgen(2 entities) | 21 | $361 |
| Bayer | 16 | $309 |
| Travere Therapeutics, Inc. | 19 | $300 |
| Vifor Pharma, Inc. | 14 | $239 |
| OPKO Pharmaceuticals, LLC | 14 | $227 |
| Otsuka America Pharmaceutical, Inc. | 10 | $196 |
| Boehringer Ingelheim | 8 | $175 |
| Fresenius USA Marketing, Inc. | 8 | $166 |
| AstraZeneca(2 entities) | 9 | $138 |
| Scpharmaceuticals Inc. | 7 | $136 |
| Calliditas Therapeutics US Inc. | 7 | $134 |
| Aurinia Pharma U.S., Inc. | 5 | $110 |
| Lilly USA, LLC | 3 | $74 |
| Novo Nordisk | 2 | $49 |
| Novartis | 3 | $46 |
| Apellis Pharmaceuticals, Inc. | 2 | $39 |
| Daiichi Sankyo Inc. | 2 | $36 |
| Cumberland Pharmaceuticals, Inc. | 2 | $31 |
| Mallinckrodt Enterprises LLC | 2 | $29 |
| Ultragenyx Pharmaceutical Inc. | 1 | $26 |
| Akebia Therapeutics Inc | 2 | $26 |
| Paratek Pharmaceuticals, Inc. | 2 | $25 |
| Shield Therapeutics Inc | 1 | $21 |
| Merck | 1 | $20 |
| Johnson & Johnson | 1 | $19 |
| GSK | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Mallinckrodt Hospital Products Inc. | 1 | $16 |
| Recordati_rare_diseases_inc. | 1 | $16 |
| Boston Scientific | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,435 in reported general payments places this provider in the 80th percentile of 165 nephrology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 82 | $63,764 |
| JardianceEmpagliflozin | 58 | $44,441 |
| KerendiaFinerenone | 45 | $36,219 |
| VeltassaPatiromer Calcium Sorbitex | 16 | $14,842 |
| Potassium Chloride | 103 | $2,282 |
| Torsemide | 137 | $2,168 |
| Sevelamer Carbonate | 20 | $1,822 |
| Calcitriol | 185 | $1,802 |
| Clonidine | 11 | $1,683 |
| Potassium Citrate ErPotassium Citrate | 14 | $1,352 |
| Doxazosin Mesylate | 82 | $1,271 |
| Vitamin D2Ergocalciferol (Vitamin D2) | 74 | $1,179 |
| Chlorthalidone | 69 | $1,133 |
| Amlodipine Besylate | 242 | $1,034 |
| Metoprolol Succinate | 35 | $990 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $138 | $63,76482 claims |
| Boehringer IngelheimJardiance | $175 | $44,44158 claims |
| BayerKerendia | $309 | $36,21945 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 165 nephrology providers in Kentucky.
Other nephrology in Edgewood
- Emily KennerEdgewood$5K
- Isaac ThomasEdgewood$3K
- Danny WooLouisville$427K
- Dawn CasterLouisville$193K
- Javier Neyra LozanoLexington$181K
- Kurt SowersHazard$119K
- Nizar AttallahLouisville$113K
- Ravinder BhagrathPikeville$84K
- Shafic Abdul Wahab El HindiLouisville$45K
- George AronoffLouisville$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.